A novel hydrolysis-resistant lipophilic folate derivative enables stable delivery of targeted liposomes in vivo

Int J Nanomedicine. 2014 Sep 29:9:4581-95. doi: 10.2147/IJN.S69115. eCollection 2014.

Abstract

Instability of targeting ligand is a roadblock towards successful development of folate targeted liposomes. Folate ligands have been linked to polyethylene glycol (PEG) and cholesterol by an amide bond to form folate-CONH-PEG-CONH-Cholesterol (F-CONH-PEG-CONH-Chol), which is subject to hydrolysis. To increase the stability of folate ligands and promote the long circulation and targeting effects, we synthesized a chemically stable lipophilic folate derivative, folate-CONH-PEG-NH-Cholesterol (F-CONH-PEG-NH-Chol), where the amide bond was replaced by a C-N bond, to deliver liposomal doxorubicin (Dox). Its physical stability, cellular uptake, cellular toxicity, pharmacokinetics, distribution, anti-tumor efficacy, and cardiac toxicity were investigated. Our results indicate that F-CONH-PEG-NH-Chol conjugated liposomes are taken up selectively by folate receptor-positive HeLa and KB cells. Compared with F-CONH-PEG-CONH-Chol with two carbonate linkages, F-CONH-PEG-NH-Chol better retained its drug entrapment efficiency and folate receptor-targeting activity during prolonged circulation. F-CONH-PEG-NH-Chol thus represents a physically stable and effective ligand for delivering folate receptor-targeted liposomes, with prolonged circulation time and efficient tissue distribution, as well as higher efficacy and less cardiac toxicity. Collectively, these results suggest that this novel conjugate can serve as a promising derivative for the delivery of anti-tumor therapeutic agents.

Keywords: FR-targeting; doxorubicin; folate ligand; liposome; stability.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / blood
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacokinetics*
  • Antineoplastic Agents / pharmacology
  • Cell Survival / drug effects
  • Cholesterol / chemistry
  • Doxorubicin / blood
  • Doxorubicin / chemistry
  • Doxorubicin / pharmacokinetics*
  • Doxorubicin / pharmacology
  • Drug Delivery Systems / methods*
  • Drug Stability
  • Folic Acid / chemistry
  • Folic Acid / pharmacokinetics*
  • HeLa Cells
  • Humans
  • Liposomes / chemistry
  • Liposomes / pharmacokinetics*
  • Liposomes / toxicity
  • Male
  • Mice
  • Tissue Distribution

Substances

  • Antineoplastic Agents
  • Liposomes
  • Doxorubicin
  • Folic Acid
  • Cholesterol